294,392 Shares in Humacyte, Inc. $HUMA Acquired by Nuveen LLC

Nuveen LLC acquired a new stake in Humacyte, Inc. (NASDAQ:HUMA) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 294,392 shares of the company’s stock, valued at approximately $502,000. Nuveen LLC owned approximately 0.19% of Humacyte at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. acquired a new position in Humacyte in the 4th quarter valued at $58,000. Hsbc Holdings PLC acquired a new position in Humacyte in the 4th quarter valued at $62,000. Crestline Management LP acquired a new position in Humacyte in the 4th quarter valued at $66,000. BNP Paribas Financial Markets acquired a new position in shares of Humacyte in the 4th quarter valued at approximately $74,000. Finally, Columbia Advisory Partners LLC acquired a new position in shares of Humacyte in the 1st quarter valued at approximately $27,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Barclays assumed coverage on shares of Humacyte in a research report on Wednesday, August 27th. They issued an “overweight” rating and a $3.50 target price for the company. HC Wainwright dropped their target price on shares of Humacyte from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, August 12th. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Monday, August 11th. Benchmark lowered their price target on Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. Finally, TD Cowen lowered their price target on Humacyte from $5.00 to $3.50 and set a “buy” rating for the company in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $9.75.

Humacyte Stock Performance

HUMA opened at $1.46 on Friday. Humacyte, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $6.77. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 1.93. The firm has a market capitalization of $231.22 million, a price-to-earnings ratio of -3.24 and a beta of 1.87. The company’s 50 day moving average price is $2.09 and its two-hundred day moving average price is $2.21.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Monday, August 11th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). The business had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.94 million. As a group, research analysts predict that Humacyte, Inc. will post -1.27 earnings per share for the current year.

Insider Activity

In other news, Director Brady W. Dougan sold 591,685 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total value of $934,862.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Laura E. Niklason sold 591,685 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total value of $934,862.30. The disclosure for this sale can be found here. In the last three months, insiders sold 4,482,090 shares of company stock valued at $7,466,382. Insiders own 5.10% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.